FDG-PET reveals dysregulated glucose metabolism as a common feature across late-onset neurodegenerative diseases with unique patterns.
This meta-analysis evaluated glucose metabolic dysregulation in the brains of adults with late-onset age-associated neurodegenerative diseases (A2ND), including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis, compared against healthy, unimpaired controls. The study population comprised 5,412 individuals with A2ND and 3,549 controls. Researchers employed activation likelihood estimation (ALE) meta-analyses to identify common signatures of dysregulated glucose metabolism on FDG-PET, alongside secondary outcomes such as cluster peak coordinates and hyper- or hypometabolism patterns.
The primary finding was that dysregulated glucose metabolism serves as a unifying feature across all A2ND conditions. However, distinct neuroanatomical metabolic patterns were observed that were unique and specific to individual diseases. Furthermore, neurological functionalities were found to be associated with these unique and complex metabolic patterns. The analysis utilized secondary outcomes including cluster-wise t- or Z- values and annotations indicating the specific disease of interest to map these variations.
Safety and tolerability data were not reported in this study. The authors note a key limitation regarding the interpretation of hypermetabolism, suggesting it may reflect a compensatory, maladaptive, or neuroinflammatory signal that requires focused investigation. Consequently, the practice relevance suggests that prevention and treatment efficacy for A2ND may depend on addressing bidirectional metabolic dysregulation in addition to disease-specific drivers of pathology.